Visual summary
KDIGO 2026 anemia guidance is final. Distinguish iron eligibility, iron withholding, and ESA targets; a normal Hb is not the treatment goal.
Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.
Diagram description
Red-cell production needs iron and a marrow signal. Available iron — Interpret ferritin and transferrin saturation; Erythropoietin signal — Kidney disease can reduce the signal; Marrow → red cells — Also assess bleeding, inflammation and other causes; Hemoglobin response — Follow trend after the chosen intervention. Iron and ESA decisions differ by dialysis setting; do not normalize hemoglobin automatically. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.
Text version
Establish the cause
Start with CBC, reticulocytes, ferritin, and transferrin saturation (TSAT). Review bleeding, inflammation, B12/folate deficiency, and medications; CKD does not exclude another diagnosis. High ferritin can reflect inflammation. A falling Hb or iron deficiency warrants a cause-directed evaluation, not an automatic “renal anemia” label.
Iron criteria: NO hemodialysis
For anemia in nondialysis CKD or peritoneal dialysis, KDIGO 2026 suggests iron when ferritin <100 ng/mL AND TSAT <40%, OR ferritin 100–<300 AND TSAT <25%. Choose oral or IV by severity, tolerance, response, access, and preference. Switch to IV after 1–3 months of inadequate oral response or poor tolerance.
Iron criteria: HEMODIALYSIS
For anemia on hemodialysis, suggested initiation criteria are ferritin ≤500 ng/mL AND TSAT ≤30%; IV iron is preferred. These are treatment-entry criteria, not targets to chase. Ferritin 600 with low TSAT does not automatically mandate more iron: assess inflammation, losses, and treatment response.
Recheck iron; know when to pause
During iron treatment, check Hb, ferritin, and TSAT every 3 months in nondialysis/PD and every 1–3 months in HD; test sooner with bleeding or changing treatment. Withhold routine iron if ferritin >700 or TSAT ≥40%. Temporarily suspend during systemic infection when appropriate.
ESA: initiation differs by setting
Correct reversible causes first. In dialysis, consider ESA initiation at Hb ≤9–10 g/dL. Without dialysis, individualize—often 8.5–10—using symptoms, transfusion avoidance, stroke/thrombosis risk, and malignancy. Use the lowest effective dose with an adult Hb goal <11.5. Recheck Hb every 2–4 weeks after starting or changing dose.
Worked example: sequence the decision
Synthetic example: nondialysis CKD, Hb 9.4, ferritin 60, TSAT 16%. Investigate iron loss and replace iron before escalating to ESA. If anemia persists, discuss ESA benefits and risks. Hb 9.4 alone mandates neither ESA nor transfusion; active bleeding, ischemic symptoms, or instability changes the urgency.
Supporting evidence
- KDIGO 2026 anemia guideline: recommendations2.1–2.4,3.2.1–3.3.1 and practice points2.2,2.5,2.7,2.8,3.4.3.2
- Supporting guideline or source
- KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease.
- Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.
- A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease.
